| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $87,706,189 | 30 | 100 |
| Williams Lewis T | director | 0 | $0 | 1 | $1.48M | $-1.48M |
| SELICK HAROLD E | director | 0 | $0 | 1 | $2.52M | $-2.52M |
| MOLINA ARTURO MD | Chief Medical Officer | 0 | $0 | 6 | $4.49M | $-4.49M |
| Waddill William D. | director | 0 | $0 | 4 | $4.6M | $-4.6M |
| Giraudo Bryan | director | 0 | $0 | 2 | $5.92M | $-5.92M |
| Ali Asif | Chief Financial Officer | 0 | $0 | 5 | $15.63M | $-15.63M |
| PATEL DINESH V PH D | President and CEO | 0 | $0 | 11 | $53.06M | $-53.06M |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral …
Over the last 12 months, insiders at Protagonist Therapeutics, Inc. have bought $0 and sold $87.71M worth of Protagonist Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protagonist Therapeutics, Inc. have bought $0 and sold $29.26M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 24,000 shares for transaction amount of $160,800 was made by SELICK HAROLD E (director) on 2020‑03‑12.
| 2026-09-30 | Sale | Ali Asif | Chief Financial Officer | 58,629 0.0917% | $141.78 | $8.31M | -0.83% | |
| 2026-09-10 | Sale | PATEL DINESH V PH D | President and CEO | 7,278 0.0112% | $144.10 | $1.05M | -3.03% | |
| 2026-09-09 | Sale | PATEL DINESH V PH D | President and CEO | 63,548 0.0996% | $146.18 | $9.29M | -2.89% | |
| 2026-09-08 | Sale | PATEL DINESH V PH D | President and CEO | 54,174 0.0821% | $145.87 | $7.9M | -3.45% | |
| 2026-08-11 | Sale | PATEL DINESH V PH D | President and CEO | 34,239 0.0533% | $148.52 | $5.09M | -3.10% | |
| 2026-08-10 | Sale | PATEL DINESH V PH D | President and CEO | 65,761 0.0991% | $149.11 | $9.81M | -4.19% | |
| 2026-06-23 | Sale | Waddill William D. | director | 9,000 0.0139% | $117.94 | $1.06M | +18.22% | |
| 2026-06-10 | Sale | Waddill William D. | director | 9,000 0.0142% | $107.68 | $969,120 | +32.42% | |
| 2026-05-29 | Sale | Waddill William D. | director | 9,000 0.014% | $99.64 | $896,760 | +39.81% | |
| 2026-05-12 | Sale | PATEL DINESH V PH D | President and CEO | 75,000 0.1168% | $100.12 | $7.51M | +38.38% | |
| 2026-05-08 | Sale | Giraudo Bryan | director | 11,130 0.0174% | $100.00 | $1.11M | +38.97% | |
| 2026-05-07 | Sale | Giraudo Bryan | director | 48,000 0.0756% | $100.12 | $4.81M | +39.64% | |
| 2026-04-20 | Sale | Ali Asif | Chief Financial Officer | 1,750 0.0027% | $105.47 | $184,573 | +29.47% | |
| 2026-03-26 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 15,000 0.0241% | $104.79 | $1.57M | +31.58% | |
| 2026-03-26 | Sale | SELICK HAROLD E | director | 24,000 0.0387% | $105.00 | $2.52M | +31.58% | |
| 2026-03-26 | Sale | Ali Asif | Chief Financial Officer | 24,765 0.0396% | $104.24 | $2.58M | +31.58% | |
| 2026-03-25 | Sale | PATEL DINESH V PH D | President and CEO | 54,641 0.0829% | $101.00 | $5.52M | +28.80% | |
| 2026-02-17 | Sale | Williams Lewis T | director | 18,000 0.0288% | $82.42 | $1.48M | +48.39% | |
| 2026-02-06 | Sale | Waddill William D. | director | 20,000 0.0317% | $83.68 | $1.67M | +42.38% | |
| 2026-01-27 | Sale | PATEL DINESH V PH D | President and CEO | 4,068 0.0065% | $83.19 | $338,417 | +34.75% |
| PATEL DINESH V PH D | President and CEO | 522968 0.8082% | $73.34M | 1 | 29 | +243.28% |
| SELICK HAROLD E | director | 60845 0.094% | $8.53M | 1 | 1 | +198.8% |
| Giraudo Bryan | director | 0 0% | $0 | 2 | 2 | +243.28% |
| Papanek Julie | director | 2453255 3.7913% | $344.04M | 1 | 0 | +18.24% |
| JOHNSON & JOHNSON | 10 percent owner | 2449183 3.785% | $343.47M | 1 | 0 | +18.24% |
| CANAAN X L.P. | 10 percent owner | 2116552 3.2709% | $296.83M | 1 | 13 | +18.24% |
| Shanafelt Armen | 2099482 3.2445% | $294.43M | 1 | 0 | +18.24% | |
| LV Management Group, LLC | 10 percent owner | 2099482 3.2445% | $294.43M | 1 | 0 | +18.24% |
| Gupta Suneel | Chief Development Officer | 266983 0.4126% | $37.44M | 1 | 3 | +243.28% |
| Kalkofen Donald A. | Chief Financial Officer | 1175 0.0018% | $164,782.00 | 1 | 0 | +243.28% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$1,801,511 | 23 | 18.58% | $8.41B |
| Increased Positions | 188 | +59.31% | 12M | +16.9% |
| Decreased Positions | 143 | -45.11% | 12M | -16.61% |
| New Positions | 84 | New | 4M | New |
| Sold Out Positions | 36 | Sold Out | 7M | Sold Out |
| Total Postitions | 362 | +14.2% | 71M | +0.28% |
| Blackrock, Inc. | $819,861.00 | 14.93% | 9.4M | -226,109 | -2.35% | 2025-09-30 |
| Farallon Capital Management Llc | $540,168.00 | 9.84% | 6.2M | +24,000 | +0.39% | 2025-09-30 |
| Rtw Investments, Lp | $501,832.00 | 9.14% | 5.76M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $371,145.00 | 6.76% | 4.26M | -101,366 | -2.33% | 2025-09-30 |
| State Street Corp | $275,994.00 | 5.03% | 3.17M | -41,748 | -1.3% | 2025-09-30 |
| Bvf Inc/Il | $223,261.00 | 4.07% | 2.56M | -650,125 | -20.25% | 2025-09-30 |
| Johnson & Johnson | $213,520.00 | 3.89% | 2.45M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $166,378.00 | 3.03% | 1.91M | +870,708 | +83.9% | 2025-09-30 |
| Ubs Group Ag | $165,294.00 | 3.01% | 1.9M | -605,243 | -24.2% | 2025-09-30 |
| Deep Track Capital, Lp | $149,574.00 | 2.72% | 1.72M | -2M | -47.14% | 2025-09-30 |